Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045220 | 1.00 | KDM1A (1.00) | KDM1ACYP2C19MEN1KMT2AGLA | |
| SCHEMBL15787328 | 0.90 | KDM1A (0.81) | KDM1ACYP2C19MEN1KMT2AGLA | |
| SCHEMBL13380621 | 0.89 | KDM1A (0.79) | KDM1A | |
| SCHEMBL15784662 | 0.85 | KDM1A (0.72) | KDM1A | |
| SCHEMBL12344215 | 0.82 | KDM1A (0.69) | KDM1AMEN1KMT2A | |
| SCHEMBL21064892 | 0.78 | KDM1A (0.64) | KDM1A | |
| SCHEMBL25983177 | 0.77 | KDM1A (0.62) | KDM1A | |
| SCHEMBL10108196 | 0.77 | KDM1A (0.62) | KDM1A | |
| SCHEMBL19161737 | 0.77 | KDM1A (0.62) | KDM1A | |
| SCHEMBL14289035 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013424-B1 | LSD INHIBITORS FOR MODULATING CANCER STEM CELLS | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2024-09-25 | — | — | EP | disclosed |
| CN-117159715-A | New use of inhibitor and inhibitor screening model | 中国农业大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | IDEAYA BIOSCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | AHR, MCL1, ARNT | KDM1A 474/4885CYP2C19 1935/4885MEN1 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.